Thirteen reasons why B cell may not be the best therapeutic target in systemic lupus erythematosus.

[Thirteen reasons why B cell may not be the best therapeutic target in systemic lupus erythematosus]. Rev Med Interne. 2018 May 28;: Authors: Chiche LY PMID: 29853262 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Related Links:

Conditions:   Lupus Erythematosus;   Lupus Nephritis Interventions:   Drug: Itolizumab [Bmab 600];   Drug: EQ001 Placebo Sponsors:   Equillium;   Biocon Limited Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Autoimmune Diseases Interventions:   Drug: Standard dose of rituximab;   Drug: Individualized dose of rituximab Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Lupus Erythematosus;   Lupus Nephritis Interventions:   Drug: Itolizumab [Bmab 600];   Drug: EQ001 Placebo Sponsors:   Equillium;   Biocon Limited Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Autoimmune Diseases Interventions:   Drug: Standard dose of rituximab;   Drug: Individualized dose of rituximab Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Several reports have highlighted the abnormal increments of serum immunoglobulin free light chains (FLC) in the course of systemic autoimmune rheumatic diseases (SARD) but a comparative analysis among different conditions is still lacking. A strong association between elevated FLC and HCV-related mixed cryoglobulinaemia (HCVMC) has been well established. Here, we aimed to analyze serum FLC levels in patients with four different SARDs in comparison with HCVMC. Using a turbidimetric assay, free k and λ chains were quantified in sera from 198 SARD patients (37 Rheumatoid Arthritis, RA; 47 Systemic Lup...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
AbstractA Euro-Lupus regimen of low-dose intravenous cyclophosphamide (CFA) is commonly used to treat severe organ manifestations of systemic lupus erythematosus (SLE), particularly lupus nephritis (LN). There are no data on the distributions and dynamics of immune cell populations in patients with various treatment outcomes. The circulating immune cells of 11 female SLE patients were assessed before and after Euro-Lupus regimen (cumulative dose of 3000  mg CFA) by flow cytometry together with those of 16 healthy women. A subanalysis was performed in LN patients who achieved complete remission(CR;n  =  3...
Source: Archivum Immunologiae et Therapiae Experimentalis - Category: Allergy & Immunology Source Type: research
Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by increased production of autoantibodies, which commonly target nuclear antigens, and concomitant deposition of immune complexes that cause inflammation in tissues. SLE is often associated with increased systemic expression of type I interferons, in some cases due to dysregulation in nucleic acid-sensing innate pathways. There is strong genetic evidence for a link between cytoplasmic RNA sensing pathways (RIG-I/MDA5) and SLE, both in human patients and murine models, however questions still remain regarding pathway initiation, cell types involved a...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Breastfeeding Medicine, Ahead of Print.
Source: Breastfeeding Medicine - Category: Perinatology & Neonatology Authors: Source Type: research
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 12 November 2019, highlighting Roche data in lupus nephritis presented at the American Society of Nephrology (7 - 10 Nov) as well as the American College of Rheumatology Annual Meetings (8 - 13 Nov) in Washington, DC and Atlanta, United States, respectively.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Updated Date: Tue, 15 Oct 2019 00:00:00 EDT
Source: DailyMed Drug Label Updates - Category: Drugs & Pharmacology Source Type: alerts
More News: Internal Medicine | Lupus